Single‐Cell RNA‐Sequencing Reveals Cachectic Satellite Cell Population in Muscle of Male Mice With Cancer Cachexia
Journal of Cachexia, Sarcopenia and Muscle · 2026-04 · 17 (2)
DOI: 10.1002/jcsm.70260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 27.03.2026. Verfasst von Alex Brown und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Cachexia, Satellite Cells, Skeletal Muscle, Sequence Analysis, RNA, Muscle, Skeletal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ontario Graduate Scholarship (A.B.), Chilean National Agency for Research and Development Scholarship, uOttawa/CHEO Research Institute's Doctoral Fellowship for Advancement of Biological Perspectives for Exercise Interventions Across the Lifespan and a uOttawa É….
Abstract (Originalsprache)
Background
Cancer cachexia leads to decreases in body mass, lean mass and fat mass, decreased therapeutic potential and ~20% of cancer‐related deaths. While several studies have demonstrated changes to components of the muscle microenvironment with cancer cachexia, none have comprehensively assessed changes to cellular dynamics across the duration of cachexia development.
Methods
Single‐cell RNA‐sequencing was performed on hindlimb muscles of male mice with 2‐, 2.5‐ and 3.5‐week subcutaneous Lewis‐lung carcinoma tumours. Cell population changes were confirmed with flow cytometry.
Results
Body mass (−0.51 g; p = 0.0014) and lean mass (−0.85 g; p = 0.0134) were decreased at 2.5 weeks and were significantly lower than sham. Increases in fat mass were attenuated starting at 2 weeks (0.70 g; p = 0.0408) compared to sham (1.55 g), and muscle cross‐sectional area decreased at 3.5 weeks (−14.81%; p = 0.0022) compared to sham. We report a novel cachexia‐associated satellite cell subcluster, comprising 71.1% of the population at 3.5 weeks, corresponding with a +20.33% increase in cell size ( p = 0.0266) and +19.73% increase in the proportion of activated PAX7 + MYOD + cells after 24 h cultured on individual myofibres ( p = 0.0226). This cachexia‐associated subcluster was also present in C26 tumour‐bearing mice and had a unique gene expression signature compared to other muscle wasting disorders. The cachexia‐associated subcluster was enriched for signalling pathways (IL‐17, TNF, p53, NF‐κB, FoxO, adipocytokines, NOD‐like receptor, MAPK and JAK–STAT) implicated in satellite cell dysfunction in cancer cachexia. Prior to the emergence of cachexia‐associated satellite cells, increases in CD11b + (+928.01%; p < 0.0001), Ly6C low (+1080.85%; p < 0.0001), Ly6C high (+920.33%; p = 0.0002), F4/80 + CD206 − (+299.22%; p = 0.0039), F4/80 + CD206 + (+1466.40%; p < 0.0001) immune cell populations were observed at 2 weeks compared to sham and returned to baseline by 2.5 weeks. There was also an increase in PDGFRα + fibro‐adipogenic progenitors at 2 weeks (+53.44%; p = 0.0398) and decreased CD31 + endothelial cells at 2 weeks (−57.37%; p = 0.0014) and 3.5 weeks (−39.78%; p = 0.0213) compared to sham, with no change in ITGA7 + satellite cells ( p = 0.4271). Cell communication analyses revealed a decline in cell communication with cancer cachexia in all cells except for monocytes/macrophages, and a decrease in cell adhesion‐related signalling in cachexia‐associated satellite cells, which is important for satellite cell differentiation, and may help to explain differentiation defects with cachexia.
Conclusions
We describe a novel satellite cell subcluster unique to cachexia. We also identified increased immune cell and fibroadipogenic progenitor content and decreased endothelial cell content that precede muscle wasting with cancer, suggesting a role for these cell populations in satellite cell dysfunction and muscle atrophy in this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Program in Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- School of Human Kinetics, Faculty of Health Science, University of Ottawa, Ottawa, Ontario, Canada.
- Éric Poulin Centre for Neuromuscular Disease, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Nadine Wiper-Bergeron
Förderung
- Ontario Graduate Scholarship (A.B.)
- Chilean National Agency for Research and Development Scholarship
- uOttawa/CHEO Research Institute's Doctoral Fellowship for Advancement of Biological Perspectives for Exercise Interventions Across the Lifespan and a uOttawa É…
- uOttawa Brain and Mind Research Institute (N.C.)
- Queen Elizabeth II Graduate Scholarship in Science and Technology
- Canadian Institute of Health Research (CIHR) Master's Graduate Scholarship
- University of Ottawa
- Canadian Institutes of Health Research
Zitieren
APA
Brown, A., Collao, N., Saleh, A., Strong, N., De Lisio, M., & Wiper-Bergeron, N. (2026). Single‐Cell RNA‐Sequencing Reveals Cachectic Satellite Cell Population in Muscle of Male Mice With Cancer Cachexia. Journal of Cachexia, Sarcopenia and Muscle, 17(2). https://doi.org/10.1002/jcsm.70260
Vancouver
Brown A, Collao N, Saleh A, Strong N, De Lisio M, Wiper-Bergeron N. Single‐Cell RNA‐Sequencing Reveals Cachectic Satellite Cell Population in Muscle of Male Mice With Cancer Cachexia. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(2). doi:10.1002/jcsm.70260
BibTeX
@article{Brown2026,
author = {Brown, Alex and Collao, Nicolás and Saleh, Aisha and Strong, Natasha and De Lisio, Michael and Wiper-Bergeron, Nadine},
title = {Single‐Cell RNA‐Sequencing Reveals Cachectic Satellite Cell Population in Muscle of Male Mice With Cancer Cachexia},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
volume = {17},
number = {2},
doi = {10.1002/jcsm.70260}
}
EUVIMED